Journal of Medicine and Life Science

  • 제16권1호
  • /
  • Pages.6-9
  • /
  • 2019
  • /
  • 1738-1010(pISSN)
  • /
  • 2671-4922(eISSN)
제주대학교 의과학연구소 (Institute for Medical Science)
권호 표지
DOI QR코드

DOI QR Code

Effects of 7~11 cycles adjuvant FOLFOX chemotherapy on the prognosis of patients with stage III colon cancer

  • Rhee, Jiyoung (Division of Hematology-Oncology, Department Internal Medicine, Jeju National University Hospital) ;
  • Jo, Jaemin (Division of Hematology-Oncology, Department Internal Medicine, Jeju National University Hospital)
  • 투고 : 2018.12.10
  • 심사 : 2019.01.28
  • 발행 : 2019.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy for 6 months is the standard treatment of stage III colon cancer to improve patient survival. Recent studies have shown that restricting the treatment to 3 months to reduce toxicity negatively affects the outcome. However, the effect of FOLFOX treatment for a duration of between 3 and 6 months(7~11 cycles) on survival is not known. The effect of a reduced duration of FOLFOX chemotherapy on the prognosis of stage III colon cancer was examined. The 5-year disease-free survival in patients receiving 7~11 cycles of FOLFOX was lower than those receiving 12 cycles(72.9% vs. 87%, respectively). Patients receiving 7~11 cycles who had a bowel obstruction at diagnosis had a significantly higher recurrence rate (66.7% vs. 15.0%) and shorter median disease-free survival (24.7 months vs. not reached) than those receiving 12 cycles. Among patients receiving 12 cycles of FOLFOX, there was no difference in the outcome between those with and those without intestinal obstructions at diagnosis. These results suggest that the completion of 12 cycles FOLFOX chemotherapy is important to improve the patient's prognosis, especially for with intestinal obstructions at diagnosis.

키워드

참고문헌

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. https://doi.org/10.3322/caac.20107
  2. Jung KW, Won YJ, Kong HJ, Lee ES. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015. Cancer Res Treat 2018;50:303-16. https://doi.org/10.4143/crt.2018.143
  3. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51. https://doi.org/10.1056/NEJMoa032709
  4. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011;29:1465-71. https://doi.org/10.1200/JCO.2010.33.6297
  5. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16. https://doi.org/10.1200/JCO.2008.20.6771
  6. Andre T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 2007;25:3732-8. https://doi.org/10.1200/JCO.2007.12.2234
  7. O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ, Jr., Erlichman C, Shepherd L, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998;16:295-300. https://doi.org/10.1200/JCO.1998.16.1.295
  8. Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 2005;39:128-35. https://doi.org/10.1345/aph.1E319
  9. Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med 2018;378:1177-88. https://doi.org/10.1056/NEJMoa1713709
  10. Andre T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, et al. Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, international duration evaluation of adjuvant (IDEA) France, Phase III Trial. J Clin Oncol 2018;36:1469-77. https://doi.org/10.1200/JCO.2017.76.0355
  11. Kim SH, Kim W, Kim JH, Woo MK, Baek JY, Kim SY, et al. A Prospective study of chronic oxaliplatin-induced neuropathy in patients with colon cancer: long-term outcomes and predictors of severe oxaliplatin-induced neuropathy. J Clin Neurol 2018;14:81-9. https://doi.org/10.3988/jcn.2018.14.1.81
  12. Baek KK, Lee J, Park SH, Park JO, Park YS, Lim HY, et al. Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer. Cancer Res Treat 2010;42:185-90. https://doi.org/10.4143/crt.2010.42.4.185
  13. Lonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, et al. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. Ann Oncol 2016;27:2074-81. https://doi.org/10.1093/annonc/mdw404